Cardiovascular death

Disease3 papers

Humans2

Latest

84

American Heart JournalHuman trial11 h

Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)

Cardiovascular disease

AtherosclerosisHumans11 h

Inflammation and lipoprotein(a) as predictors of cardiovascular events across baseline risk levels - results from the UK Biobank

European Stroke JournalHuman trialYesterday

Intensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial

Cardiovascular disease

Scientific ReportsHumans4 Oct

Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study

Journal of ElectrocardiologyHumans3 Oct

Association of pre-transplant electrocardiogram with long-term cardiovascular events in liver transplant recipients

medRxivHumansPreprint3 Oct

Limited incremental value of three complete-blood-count inflammatory indices for cardiovascular mortality: a development and external validation study in 30,533 US adults

National Institute of Diabetes and Digestive and Kidney Diseases, BethesdaReview2 Oct

Sotagliflozin

SGLT2 inhibitors

Research SquareHumansPreprint1 Oct

Association of Subclinical Airflow Obstruction with Cardiovascular Mortality and the Exploratory Statistical Indirect Effect of the Systemic Immune-Inflammation Index: A Cohort Study Based on NHANES 2007-2012

Cardiovascular disease

European Journal of Heart FailureReview1 Oct

Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement

Cardiovascular-kidney-metabolic syndrome

LancetHuman trial1 Oct

Orforglipron matches insulin glargine on cardiovascular safety

Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine…Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.

GLP-1 receptor agonists